Clinical trials have demonstrated that osimertinib significantly improves progression-free survival (PFS) and overall survival (OS) rates in patients with EGFR-mutated NSCLC. Patients treated with osimertinib often experience a reduction in tumor size and delayed disease progression compared to those treated with earlier-generation EGFR inhibitors. The drug also has a favorable side effect profile, making it a well-tolerated option for long-term use.
